[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629918":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":21,"responsibleParty":40,"collaborators":7,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":7,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Tomsk National Research Medical Center of the Russian Academy of Sciences","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Alla A. Garganeeva, MD, PhD","Tomsk NRMC","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+7 (3822) 56 52 75","aag@cardio-tomsk.ru",{"name":19,"role":15,"phone":16,"phoneExt":7,"email":20},"Elena A. Kuzheleva, MD, PhD","kea@cardio-tomsk.ru",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Cardiology Research Institute, Tomsk National Research Medical Center Russian Academy of Sciences","RECRUITING","Tomsk","Tomsk Oblast","634050","Russia","RU",{"type":31,"coordinates":32},"Point",[33,34],84.98216,56.50049,{"lat":34,"lon":33},[37],{"name":38,"role":15,"phone":39,"phoneExt":7,"email":20},"Елена Кужелева, PhD","+7 (3822) 565275",{"type":12,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Elena A. Kuzheleva","Researcher","100629918","risk-stratification-of-mace-in-heart-failure-patients-who-undergoing-cabg-100629918",false,"NCT07480915","Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG","Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study","PROFILE-HF","Inclusion Criteria:\n\n* Heart Failure\n* Planned coronary artery bypass grafting\n\nExclusion Criteria:\n\n* Myocardial infarction\n* Stroke\n* Presence of implanted devices;\n* Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm);\n* Severe renal dysfunction (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2);\n* Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases.","ALL",{"count":53,"type":54},160,"ESTIMATED","OBSERVATIONAL","PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).\n\nThe objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.\n\nThe study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.",[58,59,60],"Heart Failure","CAD - Coronary Artery Disease","CABG",[58,62,60,63,64,65,66],"Coronary Artery Disease","Coronary Artery Bypass Grafting","GDF-15","Growth differentiation factor - 15","Prognosis","2026-03-13",{"date":69,"type":70},"2026-03-18","ACTUAL",{"date":72,"type":70},"2026-03-04",{"date":74,"type":54},"2028-03",{"name":5,"class":6},1]